Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
221 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06031805 | PRostate Olaparib Real World Evidence Study(PROWESs) | active not recruiting | — | 159 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 57 | Aragon Pharmaceuticals, Inc.INDUSTRY | 4 | Sep 25, 2026 |
| NCT06894511 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC(PSMAndARPI) | active not recruiting | Phase 2 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04104893 | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation(CHOMP) | active not recruiting | Phase 2 | 40 | VA Office of Research and DevelopmentFED | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05011188 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Rahul AggarwalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06380738 | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)(PROceed) | active not recruiting | — | 111 | AstraZenecaINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02522715 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02703623 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 196 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | active not recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer(rechARge) | active not recruiting | Phase 3 | 960 | CelgeneINDUSTRY | 23 | Sep 8, 2026 | clinicaltrials |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 85 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07285694 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | active not recruiting | Phase 1 / Phase 2 | 190 | Arsenal Biosciences, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | active not recruiting | Phase 3 | 110 | AstraZenecaINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04090528 | pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | University of Wisconsin, MadisonOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT06305598 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03419234 | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | active not recruiting | Phase 2 | 223 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT02893917 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03517969 | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05828082 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06228404 | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | active not recruiting | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06895811 | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | active not recruiting | Phase 1 | 3 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT06004661 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | active not recruiting | Phase 2 | 23 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 10, 2026 | clinicaltrials |
| NCT06029998 | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion(BORXPTEN) | active not recruiting | Phase 2 | 22 | University of UtahOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer(ENZA-p) | active not recruiting | Phase 2 | 162 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658573 | AI Multimodal Model for Predicting CRPC Progression Risk(AI-MM_CPRC) | active not recruiting | — | 500 | Guangxi Medical UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT03344211 | Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT04070209 | Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) | active not recruiting | Phase 2 | 66 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer(OU-SCC-EXCITE) | active not recruiting | Phase 1 | 15 | University of OklahomaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC(PRESERVE-006) | active not recruiting | Phase 1 / Phase 2 | 148 | OncoC4, Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT02312557 | Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | active not recruiting | Phase 2 | 58 | OHSU Knight Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04769817 | ProsTIC Registry of Men Treated With PSMA Theranostics | active not recruiting | — | 500 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07553988 | A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 120 | R-Pharm International, LLCINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials